MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Chemistry World
August 1, 2014
Sarah Houlton
Amgen to shed 2400-2900 jobs Most of the job losses will be in the US, predominantly at the former Immunex research facility in Seattle and two biologics manufacturing sites in Colorado. mark for My Articles similar articles
Chemistry World
March 13, 2015
Rebecca Trager
Amgen to axe 300 Onyx employees US biotech Amgen plans to shutter the south San Francisco, US facility of Onyx Pharmaceuticals, the oncology specialist that it acquired in September 2013. mark for My Articles similar articles
Chemistry World
June 4, 2015
Phillip Broadwith
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts. mark for My Articles similar articles
The Motley Fool
July 12, 2004
Ben McClure
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. mark for My Articles similar articles
The Motley Fool
July 21, 2005
Tom Taulli
Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey. mark for My Articles similar articles
The Motley Fool
March 29, 2004
Jeff Hwang
Amgen Deals Again Two years after acquiring Immunex, Amgen takes Tularik. mark for My Articles similar articles
Chemistry World
October 12, 2015
Rebecca Trager
Monsanto plans 2600 layoffs The cuts, which will slash the company's workforce by about 12%, are part of a cost-saving plan to address declining sales of its biotech seeds and herbicides. mark for My Articles similar articles
The Motley Fool
March 15, 2007
Brian Lawler
Amgen vs. Intel: Amgen In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Why Amgen deserves to win this match-up. mark for My Articles similar articles
Chemistry World
October 23, 2008
Matt Wilkinson
Merck to slash more jobs Beleaguered US pharma giant, Merck & Co., has announced new restructuring plans that will see the company cut 7,200 jobs in an effort to save up to $4.2 billion mark for My Articles similar articles
The Motley Fool
October 24, 2006
Brian Lawler
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. mark for My Articles similar articles
The Motley Fool
April 24, 2007
Brian Lawler
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices. mark for My Articles similar articles
The Motley Fool
April 21, 2011
Luke Timmerman
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis. mark for My Articles similar articles
BusinessWeek
June 4, 2007
Gene G. Marcial
Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled. mark for My Articles similar articles
Chemistry World
January 20, 2012
Sarah Houlton
Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business. mark for My Articles similar articles
The Motley Fool
October 29, 2007
Brian Lawler
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. mark for My Articles similar articles
The Motley Fool
November 8, 2011
Brian Orelli
This Biotech Thinks It's Cheap Amgen thinks its investors aren't valuing the company properly. It's offering to repurchase $5 billion worth of stock -- about 10% of its value -- and even willing to borrow the cash to get it done. mark for My Articles similar articles
The Motley Fool
November 16, 2004
Charly Travers
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. mark for My Articles similar articles
The Motley Fool
January 29, 2007
Brian Lawler
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap. mark for My Articles similar articles
The Motley Fool
December 16, 2003
Rick Aristotle Munarriz
Amgen's Cannibalistic Ways Amgen's prospects look good, and it is planning a large share buyback. mark for My Articles similar articles
The Motley Fool
April 25, 2011
Brian Orelli
Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn. mark for My Articles similar articles
The Motley Fool
October 25, 2011
Brian Orelli
Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway. mark for My Articles similar articles
The Motley Fool
February 23, 2005
Brian Gorman
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies. mark for My Articles similar articles
The Motley Fool
October 7, 2004
Charly Travers
Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful. mark for My Articles similar articles
The Motley Fool
December 26, 2006
Brian Lawler
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. mark for My Articles similar articles
BusinessWeek
May 15, 2006
Arlene Weintraub
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors. mark for My Articles similar articles
Inc.
May 1, 2002
Kenneth Klee
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... mark for My Articles similar articles
BusinessWeek
March 22, 2004
Arlene Weintraub
Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work? mark for My Articles similar articles
BusinessWeek
September 19, 2005
Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect. mark for My Articles similar articles
The Motley Fool
May 27, 2009
Brian Orelli
A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452. mark for My Articles similar articles
Chemistry World
October 14, 2013
Phillip Broadwith
5000 jobs to be cut at Teva Israeli generics heavyweight Teva is accelerating its previously announced costcutting drive. mark for My Articles similar articles
The Motley Fool
April 28, 2008
Brian Lawler
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. mark for My Articles similar articles
Managed Care
May 2004
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. mark for My Articles similar articles
IndustryWeek
June 1, 2004
Tonya Vinas
Amgen's Land Of Discovery Biotechnology behemoth Amgen Inc., based in Thousand Oaks, Calif., further capitalized on its acquisition of Immunex Corp. with the opening of a $625 million research and development campus in Seattle in February. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Eric Bleeker
Where Amgen Is Finding Its Growth Five years ago, Amgen collected 83% of its sales from the United States. mark for My Articles similar articles
The Motley Fool
March 28, 2008
Brian Orelli
Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company. mark for My Articles similar articles
The Motley Fool
June 28, 2004
Alyce Lomax
Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial. mark for My Articles similar articles
The Motley Fool
November 2, 2010
Jeremy Phillips
Time to Sell Amgen? We're seeking danger signs among Fools' most beloved stocks. mark for My Articles similar articles
The Motley Fool
November 9, 2006
Karl Thiel
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. mark for My Articles similar articles
Bio-IT World
July 14, 2004
Not Just a Day at the Beach Joseph Panetta recalls leaving the comfort of a pharma job in Philadelphia for a position in biotech in San Diego, whose fledgling biotech community survived stormy nascent years to mushroom into a biotech hotbed. mark for My Articles similar articles
The Motley Fool
December 20, 2011
Luke Timmerman
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars? mark for My Articles similar articles
The Motley Fool
June 7, 2007
Brian Lawler
Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline. mark for My Articles similar articles
The Motley Fool
May 15, 2006
Brian Gorman
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2013
Peter Young
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. mark for My Articles similar articles
IndustryWeek
November 1, 2002
Tonya Vinas
Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run. mark for My Articles similar articles
The Motley Fool
November 28, 2011
A Brief History of Amgen's Returns Amgen shares declined 17% over the past decade. What has happened? mark for My Articles similar articles
The Motley Fool
April 29, 2005
Charly Travers
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2005
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. mark for My Articles similar articles
Global Services
May 28, 2008
Imrana Khan
Number of Layoffs in the U.S. Touches a 19-Month High Interestingly, the ever-blamed outsourcing became the reason for only 3,576 job cuts in the country. Market conditions, business closing, cost cutting, restructuring, demand downturn and bankruptcy were the major reasons of job cuts in April 2008. mark for My Articles similar articles
The Motley Fool
July 30, 2007
Brian Lawler
Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note. mark for My Articles similar articles
National Real Estate Investor
June 1, 2003
H. Lee Murphy
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry. mark for My Articles similar articles